Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Canatu's reactor business takes steps towards mass production and recurring revenue

By Atte RiikolaAnalyst
Canatu

Translation: Original published in Finnish on 07/14/2025 at 07:44 am EEST

Canatu announced on Friday that it has received Site Acceptance Test (SAT) approval for its first CNT100 SEMI reactor and post-processing equipment, which were delivered to a semiconductor customer in September 2024. The equipment successfully passed the extensive tests conducted on-site at the customer’s premises and met the stringent technical requirements and specifications defined in the acceptance criteria. According to the company, this confirms the CNT100 SEMI reactor’s readiness for mass production of CNT pellicle membranes.

Canatu's stock, which has been under pressure in recent months, received a significant boost from the news (+16.4%), suggesting that investors have not fully believed in the completion of the approval tests this year. In our view, the news reduces the technological risks associated with Canatu's reactor business, but there are still a few steps to go through before mass production starts at the customer's end.

The next step for the customer is to secure final approval for the finished carbon nanotube pellicle membrane and the entire production line before the pilot and risk mass production starts. This phase would enable the mass production of Canatu's carbon nanotube pellicle membranes, which would generate one-off revenues for the company from technology licensing and recurring revenues as royalties from the sale of carbon nanotube pellicle membranes and reactor consumables. These recurring revenues from the reactor business also form the core of the company's investment case, and we expect strong revenue growth to be weighted towards 2027-2028, when several reactors have been delivered to customers.

In its outlook provided in connection with the financial statements (our update can be found here), Canatu estimates that the approval tests for the first two delivered reactors will be completed during 2025. In this respect, things seem to be progressing according to plan, but as per our previous estimates, the first reactors are unlikely to reach mass production on the customer's end this year. Canatu also expects that any further reactor orders from existing customers will likely depend on the successful completion of the final approval tests of the first two reactors and related equipment. Based on Friday's news, we believe it is slightly more probable that Canatu will announce one or two new reactor orders before the end of the year.

Canatu is a technology company active in deep technology that creates carbon nanotubes (Canatu CNT), related products and manufacturing equipment for the semiconductor, automotive and medical diagnostics industries. The company operates through two business models, firstly using their own reactors to develop and manufacture CNT products. Second, the company sells its CNT reactors and licenses its related technology, allowing customers to produce the products themselves under a limited license.

Read more on company page

Key Estimate Figures15.06

202425e26e
Revenue22.022.835.4
growth-%62.1 %3.7 %55.1 %
EBIT (adj.)-4.8-7.5-4.0
EBIT-% (adj.)-21.9 %-32.8 %-11.4 %
EPS (adj.)-0.01-0.11-0.07
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Rarely do tenbaggers stay long at the valuation levels that made them tenbaggers, and one characteristic of this is a very high P/S. For example...
12/10/2025, 9:38 AM
by StockTycoon
5
I certainly wouldn’t value, for example, a medical device company at a P/S of ten or an automotive OEM. You can take as a comparison, for instance...
12/10/2025, 9:23 AM
by Seeras
3
You are now focusing your assessment on the semiconductor sector. In ten years, other fields might also gain momentum. Some of them might even...
12/10/2025, 8:53 AM
by StockTycoon
1
Seriously, that 10X would require a market capitalization of over 3.5 billion. If you look at Canatu’s own estimates of the market size, for...
12/10/2025, 8:38 AM
by Seeras
5
Canatu is indeed a good candidate to become a ten-bagger with a 10-year horizon, as there are other potential applications besides pellicles...
12/9/2025, 8:26 PM
by StockTycoon
3
Does Inderes believe that Cantu’s share price will increase tenfold with a 12% or even greater probability? One might infer something like that...
12/9/2025, 8:04 PM
by Volkkari
1
Look what ended up in the Model Portfolio. We bought Canatu, a manufacturer of advanced carbon nanotubes, as a new company for the Model Portfolio...
12/9/2025, 10:33 AM
by Sijoittaja-alokas
48
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.